Use of human amnion for microvascular interpositional grafts.

Area of Science:

• Biomaterials Science
• Vascular Surgery
• Regenerative Medicine

Background:

• Artificial vascular grafts often trigger inflammatory responses and acute rejection in patients.
• Amnion, a fetal membrane, has shown potential in preliminary studies for its biocompatibility.
• The need for improved vascular graft materials with reduced immunogenicity is critical.

Purpose of the Study:

• To prospectively evaluate amnion as a vascular graft material.
• To assess the efficacy of glutaraldehyde-treated amnion conduits in arterial reconstruction.
• To compare the performance of amnion grafts against control materials in a preclinical setting.

Main Methods:

• Hand-constructed tubed conduits of glutaraldehyde-treated amnion were created with varying diameters and lengths.
• These amnion grafts were used as segmental interpositional grafts in rat femoral and aortic artery defects.
• Graft morphology, antigenic reaction, blood flow, and patency were evaluated and compared to controls.

Main Results:

• Vascular grafts made from amnion demonstrated patency rates ranging from 60% to 90%.
• Remarkable reendothelialization of the amnion grafts was observed within 3 to 4 weeks post-surgery.
• Experimental amnion grafts showed favorable characteristics compared to controls in terms of morphology and blood flow.

Conclusions:

• Glutaraldehyde-treated amnion is a viable biomaterial for vascular grafting, exhibiting good patency and biocompatibility.
• Amnion grafts promote rapid reendothelialization, suggesting a reduced inflammatory response compared to synthetic grafts.
• Further investigation into amnion as a vascular graft substitute is warranted based on these promising preclinical results.